Ranolazine , 99% , 122312-55-4

CAS NO.：122312-55-4

Empirical Formula: C28H61Al16O79S8

Molecular Weight: 2349.95

MDL number: MFCD00868355

Description and Uses

Dosmalfate, a heptakis(hydrogensulfate) aluminium complex of diosmin, was launched in Spain for the prevention and treatment of gastroduodenal lesions induced by NSAID therapy. Dosmalfate can be prepared from diosmin by initial treatment with a pyridine sulfur trioxide complex followed by sodium hydroxide and finally aluminium hydroxychloride. In several pharmacological models of acute and chronic ulcers, this new cytoprotective agent has demonstrated significant protection against damage to the gastric mucosa or esophagus erosion, hemorrhage or perforation. Several mechanisms of action could be involved, partly mediated by the endogenous prostaglandins. In several clinical studies with patients receiving long-term NSAID therapy for chronic inflammatory disease, the efficacy of dosmalfate in preventing gastric ulcer was high and comparable to that of misoprostol, but with significantly less adverse events. In rats and humans, dosmalfate, administered orally at very high doses, displayed a very poor absorption and consequently, a very low incidence of side effects, particularly on CNS, cardiovascular or respiratory systems.